Table 1 Clinical features of all eligible 1216 BCa patients from TCGA, GEO and IMvigor210 cohorts
Variables | TCGA cohort | GEO cohort | IMvigor210 cohort | |
|---|---|---|---|---|
(n = 406) | (n = 462) | (n = 348) | ||
Status | ||||
 Alive | 298 (73.40) | 340 (73.59) | 116 (33.33) | |
 Dead | 108 (26.60) | 122 (26.41) | 232 (66.67) | |
Age | 68.09 ± 10.57 | 67.81 ± 11.51 | NA | |
Gender | ||||
 Female | 107 (26.35) | 111 (24.03) | 76 (21.84) | |
 Male | 299 (73.65) | 351 (75.97) | 272 (78.16) | |
AJCC—T | Response:CR | 25(7.18) | ||
 T1 | 11(2.70) | 277(59.96) | ||
 T2 | 193(47.54) | 116(25.11) | PR | 43(12.36) |
 T3 | 158(38.92) | 49(10.61) | SD | 63(18.10) |
 T4 | 44(10.84) | 20(4.32) | PD | 167(47.99) |
NE | 50(14.37) | |||
AJCC—N | Immune phenotype:inflammed | 74(21.26) | ||
 N0 | 239(58.86) | 414(89.61) | ||
 N1 | 47(11.58) | 48(10.39) | excluded | 134(38.51) |
 N2 | 76(18.72) |  | desert | 76(21.84) |
 N3 | 8(1.97) |  | ||
 Nx | 36(8.87) |  | NE | 64(18.39) |
AJCC—M | ||||
 M0 | 196(48.28) | 448(96.97) | ||
 Mx/M1 | 210(51.72) | 14(3.03) | ||
Stage I | 2(0.49) | NA | 118(33.90) | |
 II | 128(31.53) | NA | 95 (27.30) | |
 III | 140(34.48) | NA | 69 (19.833) | |
 IV | 136(33.50) | NA | 66 (18.97) | |
Tumor_grade | ||||
 High grade | 382(94.09) | 155(33.55) | NA | |
 Low grade | 21(5.17) | 234(50.65) | NA | |
 Unknown | 3(0.74) | 73(15.80) | NA | |
 Median follow-up,months(IQR) | 17.73(10.83–31.60) | 35.54(16.72–62.13) | 8.05(2.87–17.87) | |
Overall survival (95% CI) | ||||
 1 years | 85.2(83.4–87.0) | 92.0(90.7–93.3) | 3 months | 76.0(73.7–78.3) |
 3 years | 66.2(63.1–69.3) | 80.2(78.2–82.2) | 6 months | 60.7(58.7–63.4) |
 5 years | 61.3(57.8–64.8) | 70.3(67.6–73.0) | 9 months | 49.3(46.6–52.0) |
12 months | 41.2(38.5–43.9) | |||